SCHEMBL2238896

SCHEMBL2238896

OC1(C=Cc2ccncc2)CCNCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JUN P05412 1/20 0.43
NFKB1 P19838 1/20 0.43
CYP2D6 P10635 4/20 0.37
HPGD P15428 2/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C19 P33261 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP2C9 P11712 2/20 0.36
TSHR P16473 1/20 0.36
ALOX5 P09917 1/20 0.35
ADRB2 P07550 1/20 0.34
NCF1 P14598 1/20 0.34
PLD1 Q13393 1/20 0.34
KDM1A O60341 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MAPT P10636 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2238891 1.00 JUN (0.43) JUNNFKB1CYP2D6HPGDCYP3A4
Trifluoroacetic Acid SCHEMBL2238735 0.87 JUN (0.41) JUNNFKB1CYP2D6HPGDALDH1A1
Trifluoroacetic Acid SCHEMBL2238726 0.87 JUN (0.41) JUNNFKB1CYP2D6HPGDALDH1A1
SCHEMBL5236717 0.82 OPRM1 (0.42) CYP2D6ALDH1A1CYP2C9TSHRHDAC1
SCHEMBL5236707 0.82 OPRM1 (0.42) CYP2D6ALDH1A1CYP2C9TSHRHDAC1
SCHEMBL2236225 0.81 RAB9A (0.49) JUNNFKB1ALDH1A1ALOX5MAPT
SCHEMBL2236227 0.81 RAB9A (0.49) JUNNFKB1ALDH1A1ALOX5MAPT
SCHEMBL5239392 0.79 HSD11B1 (0.43) ALDH1A1ALOX5
SCHEMBL5239384 0.79 HSD11B1 (0.43) ALDH1A1ALOX5
SCHEMBL1934180 0.73 JUN (0.41) JUNNFKB1CYP2D6CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2014-03-13 US disclosed
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2014-03-13 US disclosed
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2014-03-13 US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 US disclosed
WO-2010020556-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC NEUROSCIENCES GMBH (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 JUN 2425/4885NFKB1 306/4885CYP2D6 1105/4885
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 JUN 2549/4885NFKB1 400/4885CYP2D6 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.